Literature DB >> 14747882

Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure.

Alexander Jetter1, Martina Kinzig-Schippers, Michael Illauer, Robert Hermann, Katharina Erb, Jürgen Borlak, Helga Wolf, Gillian Smith, Ingolf Cascorbi, Fritz Sörgel, Uwe Fuhr.   

Abstract

BACKGROUND AND
OBJECTIVE: The standard approach for phenotyping of the human arylamine N-acetyltransferase 2 (NAT2) uses urinary caffeine metabolite ratios after a caffeine test dose taken in after methylxanthine abstinence. We tested whether these standardization measures were still needed when a more sensitive quantification technique was used.
METHODS: A new liquid chromatography/tandem mass spectrometry (LC-MS/MS) method for the quantification of the caffeine metabolites 5-acetylamino-6-formylamino-3-methyluracil (AFMU), 5-acetylamino-6-amino-3-methyluracil (AAMU), 1-methylxanthine (1X), and 1-methylurate (1U) was developed. Urine samples from 77 healthy volunteers collected before and 5-6 h after oral intake of 150-200 mg caffeine were analyzed. The lower limits of quantification were 0.1 microg/ml for caffeine, 1X, 1U, and AFMU, and 0.2 microg/ml for AAMU.
RESULTS: The urinary NAT2 ratios (AFMU+AAMU) / (AFMU+AAMU+1X+1U) before and after caffeine intake correlated well in 65 volunteers (r(2)=0.827; P< 0.0001). In 12 participants (16%), metabolite concentrations in urine before caffeine intake were below the quantification limit. NAT2 genotyping, done in 41 volunteers for four SNPs, corroborated the phenotyping results.
CONCLUSION: NAT2 activity can be determined from a spontaneous urine probe in most subjects by quantification of caffeine metabolites arising from non-standardized dietary caffeine exposure using LC-MS/MS. This may facilitate the phenotyping procedure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14747882     DOI: 10.1007/s00228-003-0718-8

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

Review 1.  Measuring agreement in method comparison studies.

Authors:  J M Bland; D G Altman
Journal:  Stat Methods Med Res       Date:  1999-06       Impact factor: 3.021

2.  Liquid chromatographic method for the simultaneous determination of caffeine and fourteen caffeine metabolites in urine.

Authors:  E K Bendriss; N Markoglou; I W Wainer
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-09-15

3.  A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid.

Authors:  C A Smith; M Wadelius; A C Gough; D J Harrison; C R Wolf; A Rane
Journal:  J Med Genet       Date:  1997-09       Impact factor: 6.318

4.  Stability of 5-acetamido-6-formylamino-3-methyluracil in buffers and urine.

Authors:  Pierre Wong; Gérald Villeneuve; Vicky Tessier; Kris Banerjee; Hinko Nedev; Bertrand J Jean-Claude; Brian Leyland-Jones
Journal:  J Pharm Biomed Anal       Date:  2002-05-15       Impact factor: 3.935

5.  Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity.

Authors:  I Cascorbi; N Drakoulis; J Brockmöller; A Maurer; K Sperling; I Roots
Journal:  Am J Hum Genet       Date:  1995-09       Impact factor: 11.025

6.  Extractionless method for the simultaneous high-performance liquid chromatographic determination of urinary caffeine metabolites for N-acetyltransferase 2, cytochrome P450 1A2 and xanthine oxidase activity assessment.

Authors:  A Nyéki; J Biollaz; U W Kesselring; L A Décosterd
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-05-05

7.  Determination of N-acetylation phenotype using caffeine as a metabolic probe and high-performance liquid chromatography with either ultraviolet detection or electrospray mass spectrometry.

Authors:  F Baud-Camus; P Marquet; M Soursac; C Davrinche; R Farinotti
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-08-25

8.  NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios.

Authors:  A Nyéki; T Buclin; J Biollaz; L A Decosterd
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

9.  An alternative test for acetylator phenotyping with caffeine.

Authors:  B K Tang; D Kadar; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1987-11       Impact factor: 6.875

10.  Extractionless method for the determination of urinary caffeine metabolites using high-performance liquid chromatography coupled with tandem mass spectrometry.

Authors:  Heiko Schneider; Lan Ma; Hansruedi Glatt
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-06-15       Impact factor: 3.205

View more
  5 in total

1.  Urine excretion of caffeine and select caffeine metabolites is common in the U.S. population and associated with caffeine intake.

Authors:  Michael E Rybak; Maya R Sternberg; Ching-I Pao; Namanjeet Ahluwalia; Christine M Pfeiffer
Journal:  J Nutr       Date:  2015-02-04       Impact factor: 4.798

2.  Mesalazine pharmacokinetics and NAT2 phenotype.

Authors:  Hendrik Lück; Martina Kinzig; Alexander Jetter; Uwe Fuhr; Fritz Sörgel
Journal:  Eur J Clin Pharmacol       Date:  2008-08-14       Impact factor: 2.953

3.  Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?

Authors:  Alexander Jetter; Martina Kinzig; Michael Rodamer; Dorota Tomalik-Scharte; Fritz Sörgel; Uwe Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2008-12-13       Impact factor: 2.953

Review 4.  PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.

Authors:  Ellen M McDonagh; Sotiria Boukouvala; Eleni Aklillu; David W Hein; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-08       Impact factor: 2.089

5.  Determination of Urinary Caffeine Metabolites as Biomarkers for Drug Metabolic Enzyme Activities.

Authors:  Hyeong Jun Kim; Min Sun Choi; Shaheed Ur Rehman; Young Seok Ji; Jun Sang Yu; Katsunori Nakamura; Hye Hyun Yoo
Journal:  Nutrients       Date:  2019-08-19       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.